GlassScriptPhysician profile
Nadeem Kamran
NPI 1275696171
$3,228.02
in general payments reported to CMS, 2019-2025
32 companies · $713 in 2025
The $713 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.10 · 2020: $145 · 2021: $138 · 2022: $731 · 2023: $731 · 2024: $752 · 2025: $713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,195.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $608.52 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $331.67 | 2021-2024 | |
| Lilly USA, LLC | $270.55 | 2020-2024 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $246.58 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $232.21 | 2022-2024 | |
| Pfizer INC. | $202.37 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $174.55 | 2022-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $124.97 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Mylan Specialty L.P. | $96.48 | 2024 | Yupelri |
| Biohaven Pharmaceutical Holding Company LTD. | $87.65 | 2022 | |
| Glaxosmithkline, LLC. | $80.48 | 2023-2025 | Trelegy Ellipta |
| Vanda Pharmaceuticals INC. | $77.19 | 2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $74.65 | 2022-2025 | Gattex |
| Exact Sciences Corporation | $68.79 | 2024-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $60.71 | 2020-2025 | Spravato |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $48.90 | 2022 | |
| Merck Sharp & Dohme LLC | $45.82 | 2021-2023 | Dificid |
| Abbott Laboratories | $44.36 | 2024-2025 | Freestyle Libre 3 |
| Edw Pharma, INC. | $44.30 | 2022 | |
| Astellas Pharma US INC | $39.92 | 2022-2024 | Veozah |
| Viatris Specialty LLC | $37.90 | 2025 | Yupelri |
| Dexcom, INC. | $36.26 | 2024-2025 | Dexcom G6 Transmitter |
| Aimmune Therapeutics, INC. | $33.90 | 2025 | Zenpep |
| Scpharmaceuticals INC. | $28.64 | 2025 | |
| Lundbeck LLC | $21.85 | 2025 | Rexulti |
| Amgen INC. | $18.62 | 2024 | Evenity, Prolia |
| Medtronic Minimed, INC. | $18.17 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $17.03 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.60 | 2023 | Eliquis |
| Azurity Pharmaceuticals, INC. | $14.12 | 2024 | |
| Almatica Pharma LLC | $13.50 | 2023 | Gralise, Sertraline Hcl, Loreev Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadeem Kamran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.